High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Betta Pharmaceuticals Co., Ltd.30 enrolled

Overview

This trail is designed to assess the efficacy and safety of high dose Iconitib combined with SRS for NSCLC patients harboring EGFR mutation with brain metastases.

The long-term control of brain metastases becomes a clinical challenge. Whole brain radiotherapy, the standard treatment for patients with multiple brain metastases, can only bring a modest survival improvement around 3-6 months. EGFR-TKIs like icotinib with its proven activity in non-small cell lung cancer may provide clinical benefits to brain metastases patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-small Cell Lung Cancer Brain Metastases

Interventions

IcotinibDRUG

375 mg Tid (1125 mg per day) until intracranial PD.

SRSRADIATION

If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological or cytological confirmation of non-small cell lung cancer (NSCLC); * Diagnosis of brain metastases on a Gadolinium-enhanced MRI. * Less than 10 sites of intracranial metastases, or the longest diameter of the intracranial lesion is less than 4cm. * Positive EGFR mutation（Ex19del or 21L858R）. * Life expectancy ≥3months. * Have one or more measurable encephalic lesions according to RECIST. * The patient has not received radiotherapy for the head or extracranial target lesions before. * Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L. * Adequate renal function: Serum creatinine ≤1.5 x ULN, or ≥ 50 ml/min. * Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases. * Female subjects should not be pregnant. * All human subjects should able to comply with the required protocol and follow-up procedures, and able to receive oral medications. * Written informed consent provided. Exclusion Criteria: * Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux. * CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal. * Allergic to Icotinib. * Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease. * Pregnancy or breast-feeding women. * Participate in the other anti-tumor clinical trials in 4 weeks. * have quit from the trail before. * Any other serious underlying medical, psychological and other condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Locations (1)

West China Hospital

Chengdu, Sichuan, China

RECRUITING

Outcomes

Primary Outcomes

intracranial progression-free survival

Time frame: from date of randomization until the date of first documented intracranial progression, assessed up to 12 months.

Secondary Outcomes

progress-free survival

Time frame: from date of randomization until the date of extracranial progression, assessed up to 18 months.

overall survival

Time frame: from date of randomization until the date of death, assessed up to 36 months.

objective response rate

Time frame: from date of randomization until the date of progression, assessed up to 12 months.

disease control rate

Time frame: from date of randomization until the date of progression, assessed up to 18 months.

Quality of life measured by FACT-L/LCS 4.0 and FACT-Br

Time frame: from date of randomization until the date of death from any cause, assessed up to 36 months.

Central Contacts

YOU LU, M.D.

CONTACT

0086-28-85423571 radyoulu@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.